Hypertrophic Cardiomyopathy Pipeline Review, H2 2018 Featuring C&C BioPharma, Lead Discovery Center & MyoKardia – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hypertrophic
Cardiomyopathy – Pipeline Review, H2 2018”
drug pipelines has
been added to ResearchAndMarkets.com’s offering.

Hypertrophic Cardiomyopathy – Pipeline Review, H2 2018, provides
comprehensive information on the therapeutics under development for
Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also
reviews of key players involved in therapeutic development for
Hypertrophic Cardiomyopathy and features dormant and discontinued
projects. The guide covers therapeutics under Development by
Companies/Universities/Institutes; the molecules developed by Companies
in Phase III, Preclinical and Discovery stages are 1, 4 and 1
respectively. Similarly, the Universities portfolio in Preclinical
stages comprises 2 molecules, respectively.

Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision-making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Hypertrophic Cardiomyopathy – Overview
  4. Hypertrophic Cardiomyopathy – Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Hypertrophic Cardiomyopathy – Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Hypertrophic Cardiomyopathy – Companies Involved in Therapeutics
  • C&C BioPharma LLC
  • Lead Discovery Center GmbH
  • MyoKardia Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jjdcxs/hypertrophic?w=4


Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Cardiovascular


I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.com for scheduling information.